CD8A and neoplasm: Similar to what has been previously observed with KRASG12C(OFF) inhibitors, inhibition of RASG12C(ON) led to increased tumour-infiltrating CD8+ T and Treg cells (Fig. 6a, b and Supplementary Fig. 6a).